

ANTIFUNGAL SUSCEPTIBILITY PATTERN OF *CANDIDA ALBICANS* AND NON *CANDIDA ALBICANS* SPECIES ISOLATES AT A TERTIARY CARE HOSPITAL IN INDIA

ABSTRACT

Vaginitis, also known as vulvovaginal candidiasis (VVC), is a common fungal illness that affects women of all ages. After bacterial vaginosis, vulvovaginal candidiasis is the second most frequent cause of vaginitis, and it affects 40% of women who have vaginal discharge. Candida is a fungal disease and one of the most frequent human opportunistic fungus. Standard Candida isolation procedures were used to process the samples. Germ tube tests and Candida agar medium were used to identify Candida species. The disc diffusion technique was used to test antifungal sensitivity on Mueller Hinton Agar (MHA) supplemented with 2 percent glucose and 0.5 g/ ml methylene blue dye. *Candida albicans* accounted for 42 (36.3 percent) of the 350 Candida isolates, followed by *Candida glabrata* (24.1 percent), *Candida tropicalis* (22.5 percent), *Candida krusei* (12.3%), and *Candida parapsilosis* (9.7%). Amphotericin Bis is the most active antifungal drug against Candida isolates, with a sensitivity pattern of 106/116 (91.3%). Ketoconazole, on the other hand, had the highest resistance (20.6 percent). In light of the growing tide of antimicrobial resistance to fungal agents, the current study suggests that species-level identification of Candida isolates should be encouraged.

Introduction

Vulvovaginal candidiasis (VVC), sometimes called vaginitis, is a fungal infection that affects women of all ages. Vulvovaginal candidiasis is the second most common cause of vaginitis, after bacterial vaginosis, and it affects 40% of women who have vaginal discharge. Candida is a fungus that is one of the most common opportunistic fungi in humans [1]. Although the genus Candida has approximately 350 species, only a handful have been identified as causing opportunistic human disease [2]. *Candida albicans*, *Candida glabrata*, *Candida tropicalis*, *Candida krusei*, *Candida parapsilosis*, *Candida dubliniensis*, *Candida guilliermondii*, and *Candida kyle* are among the *Candida* species that cause illness in humans [3-6]. Candida species are found on the mucosal surfaces of the human gastrointestinal system, genitourinary tract, and mouth as part of the natural flora. It causes a wide range of illnesses, from minor infections to life-threatening invasive and haematogenic infections [7]. Vaginal candidiasis is the most frequent fungus that infects the female genital system across the world [8, 9]. They, along with bacteria, are the most common cause of vaginitis, which is characterised by vaginal pruritis, thick white vaginal discharge, itching, vulva inflammation, and dyspareunia

[10]. Vaginal candidiasis can be characterised as straightforward or difficult depending on the clinical presentation and antifungal treatment. The most common cause of uncomplicated vaginal Candidiasis is *Candida albicans*, which produces mild to severe symptoms. Non-albicans *Candida* species are the most prevalent cause of complex vaginal candidiasis, which is common among immunocompromised people and pregnant women. *Candida albicans* is the most common cause of VVC, however additional species classified as *Candida non-albicans* (*C. glabrata*, *C. tropicalis*, *C. krusei*, *C. parapsilosis*, *C. guilliermondii*) have also been found. The treatment of *C. glabrata*, the second most prevalent yeast, is considered a severe therapeutic challenge [11]. *Candida albicans* and *Candida non-albicans* species are closely related but differ in epidemiology, virulence characteristics, and fungal susceptibility, hence *Candida* species identification is critical for effective management [12]. The most prominent risk factors for azoles resistance among *Candida* isolates from vulvovaginitis candidiasis patients include prolonged treatment and increasing antifungal usage for recurrent candidiasis [13]. Women with vaginal candidiasis have a higher risk of contracting HIV [14]. Several investigations have found a substantial link between candida and diabetes [15-17], and premature birth [18]. Pregnancy, uncontrolled diabetes, antibiotic usage, oral contraceptive use, immunological suppression status, excessive perfume use, and contraceptive use are all risk factors for VC [19]. The treatment for VC is quite gentle and only lasts a few weeks. It is a strong risk factor for other sexually transmitted diseases if left untreated [20]. A brief course of azole-based antifungal treatment for verified cases of VC is effective, safe, and cheap [21].

MATERIAL AND METHODS

This cross-sectional investigation took place in the Department of Microbiology of a tertiary care hospital in central India from January 2018 to February 2019. The research comprised 350 individuals who complained of vaginal discharge and were seen at the Obstetrics and Gynecology department.

Specimen collection:

Specimens were taken from the vaginal or cervix with a sterile cotton swab to avoid contamination by other organisms. For each patient, two swabs were taken. One was utilised for direct smear inspection, while the other was inoculated on Sabouraud's dextrose agar and incubated aerobically at 37°C. Gram staining and a 10% KOH preparation were used to examine direct smears.

Identification: Gram staining revealed gram positive budding fungal yeast cells, which validated Candida development on Sabouraud's dextrose agar. On the basis of colony morphology and gram stain analysis, Candida growth on SDA was established. Candida species were identified after growth.

Species identification- Standard mycological procedures were used to identify Candida isolates, including the germ tube test, sugar fermentation and assimilation, colony colour on Hi Chrome Candida agar, and chlamydospore development on Corn meal agar.

Antifungal susceptibility testing: Antifungal susceptibility testing was performed by disk diffusion method using Mueller-Hinton Agar, 2% Glucose with Methylene Blue Dye Medium as per CLSI guidelines (C.L.S.I. document M44-A2, 2009.). The inoculum was made by separating five separate colonies with a diameter of about 1 mm from a Candida species culture that had been cultured for at least 24 hours. Colonies were suspended in 5 mL of sterile saline, and the turbidity was adjusted visually by comparing the transmittance of the inoculums to that of a 0.5 McFarland standard.

The disc diffusion technique was used to assess antifungal susceptibility. Using disk dispenser (Oxoid™), fluconazole disk (10 µg), itraconazole (10 µg), voriconazole (10 µg), clotrimazole (10 µg) and nystatin (100 IU) antifungal discs (Thermo Scientific™ Oxoid™) were applied on MHA (Thermo Scientific™ Oxoid™) as recommended by the Clinical Laboratory Standard Institute (CLSI) M44A document.

The plates were incubated at 37°C for 24 hours before being read. For each antifungal disc, the sizes of zones of inhibition were measured in millimetres with a ruler. The CLSI criteria were used to interpret all antifungal susceptibility tests (susceptible S, susceptible dose dependent [SDD], and resistant R) (Table 1). Quality control was carried out using American Type Culture Collection (ATCC) 90028 quality control strains.

Table 1: Interpretative breakpoints of antifungal agents

	Sensitive	intermediate/SDD	Resistant
Amphotericin B (20 µg)	≥15	10-14	<10
Fluconazole (10 µg)	≥19	15-18	≤14
Clotrimazole (10 µg)	≥20	12-19	≤11
Voriconazole (10 µg)	≥17	14-16	≤13
Nystatin (100 U)	≥15	10-14	<10

As quality control, *C. albicans* ATCC 90028 and *C. parapsilosis* ATCC 22019 were utilised. Himedia Laboratories in India provided all of the culture media, antifungal disc, and control strains.

RESULTS & DISCUSSION

350 high vaginal swabs yielded a total of 116 *Candida* species. Non-*albicans Candida* (NAC) accounted for 63.7 percent of the 116 *Candida* isolates, whereas *C. albicans* accounted for 42 percent. As indicated in figure 1, *C. glabrata* was found in 26/116 (22.4%) of NAC, followed by *C. tropicalis* in 24/116 (20.6%), *C. parapsilosis* in 16/116 (13.7%), and *C. krusei* in 10/112 (8%). Table 2 shows the results of *Candida* species speciation using *Candida* HiChrom agar color of the colony and Germ tube test. *Candida albicans* had green colour colonies and a germ tube, *Candida glabrata* had purple colour colonies and a germ tube, *Candida krusei* had pink colour colonies and a germ tube, *Candida tropicalis* had blue colour colonies and a germ tube, and *Candida parapsilosis* had cream colour colonies and a germ tube.

Table 2 shows the sensitivity pattern of different antifungal agents for the 116 *Candida* isolates tested (73 isolates, 62.9 percent) were sensitive to fluconazole, (104 isolates, 89.6%) were sensitive to Voriconazole, (86 isolate, 74.1 percent) were sensitive to Ketoconazole, (94 isolates 81 percent) were sensitive to Nystatin, and (106 isolates 99.2%) were sensitive to Amphotericin B.

In the case of *Candida albicans* (n=42), 35 isolates (83.3%) were susceptible to Fluconazole, 34 isolates (80.9%) were susceptible to Voriconazole, 32 isolates (76.1%) were susceptible to Ketoconazole, 38 isolates (90.4%) were susceptible to Nystatin, and 40 isolates (95.2%) were susceptible to Amphotericin B.

For 76 isolates of Non *albicans candida* the 26 isolates of *Candida glabrata*, (21 isolates, 80.7%) were susceptible to Fluconazole, (24 isolates, 92.3%) were susceptible to Voriconazole, (19 isolates, 73.0%) susceptible to Ketoconazole, (22 isolate 84.6%) was susceptible to Nystatin and (24isolates 92.3%) was susceptible to Amphotericin B.

Of the 24 isolates of *Candida Tropicalis*, (18 isolates, 75%) were susceptible to Fluconazole, (23 isolates, 95.8%) were susceptible to Voriconazole, (17 isolates, 70.8%) susceptible to Ketoconazole, (18 isolate 75%) was susceptible to Nystatin and (23 isolates 95.8%) was susceptible to Amphotericin B.

Of the 16 isolates of *Candida Parapsilosis*, (13 isolates, 81.2%) were susceptible to Fluconazole, (16 isolates, 100%) were susceptible to Voriconazole, (13 isolates, 81.2%) susceptible to Ketoconazole, (11 isolate 68.7%) was susceptible to Nystatin and (14 isolates 87.5%) was susceptible to Amphotericin B.

Of the 8 isolates of *Candida krusei*, (4 isolates, 50%) were susceptible to Fluconazole, (7 isolates, 87.5%) were susceptible to Voriconazole, (5 isolates, 62.5%) susceptible to Ketoconazole, (6 isolate 75%) was susceptible to Nystatin and (6 isolates 75%) was susceptible to Amphotericin B.

Table 2: Characterization of vaginal Candida isolates.

Candida species	Colony on chrome agar	Germ tube test
<i>Candida albicans</i>	Light green	+
<i>Candida glabrata</i>	Purple	+
<i>Candida tropicalis</i>	Dark blue	Later produced
<i>Candida krusei</i>	Pink	+
<i>Candida parapsilosis</i>	Cream	+

Table 3: Frequency distribution of c species in positive culture

Candida species	No of patients (n=116)	Percentage (%)
<i>C. albicans</i>	42	(36.2%)
<i>C. glabrata</i>	26	(22.4%)
<i>C. tropicalis</i>	24	(20.6%)
<i>C. parapsilosis</i>	16	(13.7%)
<i>C. Krusei</i>	10	(8.6%)




Fig1: Frequency distribution of c species in positive culture

Table 4: Antifungal susceptibility pattern of candida albicans and candida non albicans species

Candida species	Antifungal										Ketoconazole(30µg)			Nystatin (100 U)		
	Amphotericin B (20µg)			Fluconazole (10µg)			Voriconazole (10µg)			S ≥15	DDS	R <9	S ≥15	DDS	R ≤10	
	S ≥15 (%)	DDS 10-14 (%)	R ≤9 n(%)	S ≥19 n (%)	DDS 15-18 n (%)	R ≤14 n (%)	S ≥17 n (%)	DDS 14-16 n (%)	R ≤13 (%)							
<i>C. albicans</i> (n=42)	40 (95.2)	0 (0.0)	2 (4.7)	35 (83.3)	4 (9.5)	3 (7.1)	34 (80.9)	3 (8.8)	5 (19.5)	32 (80.9)	3 (8.8)	7 (16.6)	38 (90.4)	0 (0.0)	4 (9.5)	
<i>C. non albicans</i> (n=74) <i>C. glabrata</i> (n=28)	26 (92.8)	0 (0.0)	2 (7.1)	23 (82.1)	2 (7.6)	3 (11.5)	26 (92.8)	0 (0.0)	2 (7.1)	21 (75)	2 (7.6)	5 (17.85)	24 (85.7)	1 (3.5)	3 (11.5)	
<i>C. tropicalis</i> (n=25)	24 (96)	0 (0.0)	1 (4.0)	19 (76)	0 (0.0)	6 (25)	24 (96)	0 (0.0)	1 (4)	18 (72)	2 (8)	5 (20)	19 (75)	1 (4.1)	5 (20.8)	
<i>C. parapsilosis</i> (n=12)	10 (83.3)	0 (0.0)	2 (16.6)	10 (83.3)	0 (0.0)	2 (12.5)	12 (100)	0 (0.0)	0 (0.0)	9 (83.3)	2 (8)	5 (20)	9 (75)	0 (0.0)	3 (25)	
<i>C. krusei</i> (n=9)	6 (66.6%)	0 (0.0)	3 (33.3)	5 (55.5)	0 (0.0)	4 (44.4)	8 (88.8)	0 (0.0)	1 (11.1)	6 (66.6)	1 (11.1)	2 (22.2)	7 (77.7)	0 (0.0)	3 (33.3)	
Total	106 (91.37)	0 (0.0)	10 (8.6)	92 (79.3)	6 (5.1)	18 (15.5)	104 (89.6)	3 (2.5)	9 (7.7)	86 (74.1)	10 (8.6)	24 (20.6)	97 (83.6)	2 (1.7)	18 (15.5)	

S - Sensitive, DDS - Dose dependent Susceptible, R – Resistant

The rate of isolation of NAC was 63.7 percent in our investigation, compared to 36.2 percent for *C. albicans*. Kikani B et al [22] (55.6 percent vs 44.4 percent), Deepa Babin et al [23] (64.5 percent vs 35.5 percent), and Namrata et al [24] have all found higher NAC isolation than *C. albicans* (53 percent vs 47 percent). However, Tehran [25] (65.1 percent

versus 34.9 percent), Sudan [26] (92 percent vs 8%), Egypt [27] (60.3 percent vs 39.7 percent), Turkey [28] (59.9% vs 40.1 percent), and India [29] have reported greater isolation of the most prevalent species, *C. albicans*, than NAC (66 percent vs 34 percent). After *C. albicans*, *C. glabrata* was the second most prevalent isolate (24.1%) in the current investigation. In instances of VVC, it has been found to be the second most frequent isolate in Saudi Arabia [30] (31%), Turkey [31] (34.5%), Australia [32] (20%), Egypt [33] (12.7%), and India [34] (11 percent). *C. tropicalis* was the third most common isolate in the current investigation, following *C. albicans* and *C. glabrata*. *C. tropicalis* isolation rates in cases VVC ranged from 4% to 26.4 percent [34-36]. The disc diffusion technique revealed that 15.5 percent of *Candida* isolates were resistant to fluconazole in our investigation. This finding is similar to resistance reported by Lee et al [37] (17.1%) and Kustimur et al [38] (16 percent). However, Ooga et al [39] (25%) and Negri et al [40] (27%) reported greater rates of resistance, whereas Zomorodian et al [41] (3.4%), Colombo et al [42] (6%), Kikani et al [43] (8.2%), and Pfaller et al [44] reported lower rates of resistance (9.9 percent). In comparison to our study, there was a reduced rate. In our study, 7.1 percent of *C. albicans* had fluconazole resistance. Our findings are similar to those of Capoor et al [45] (21.8 percent). Doddaiah V et al [46], on the other hand, found it in 8.6% of their *C. albicans* isolates. Several workers have reported fluconazole resistance in *C. tropicalis* (10-11%) and *C. glabrata* (31-33%), but none of our isolates were resistant [47-49]. Voriconazole resistance was found in 7.7 % of our isolates. Das P et al [50] (6.45%) and Dalia Saad El Feky et al (7.9%) have come to similar conclusions. Voriconazole resistance was found in 21.1 percent of *C. albicans* isolates and 50 percent of *C. parapsilosis* isolates in our investigation. Resistance to Ketoconazole was greater (20.6 percent) than resistance to voriconazole (9.1%) in this investigation, presumably because Ketoconazole is more often used than Voriconazole. Resistance to Ketoconazole is a reason for worry, not only because it is a cost-effective therapy for candidiasis, but also because it is the most often used azole. As a result, care should be used while prescribing or using Ketoconazole. Voriconazole, on the other hand, appears to be a superior alternative, not only because of the lesser resistance seen with this antifungal, but also because of its more efficient binding to the *Candida* species [51] cytochrome P-450 isoenzyme. Resistance to Amphotericin B was found in 8.6% of *Candida* species in this investigation, compared to 1.37 percent in Kashid et al [52] and zero percent in Negri et al. [53]. In our investigation, amphotericin B resistance was found to be 4.7 percent in *C.*

albicans, which is similar to the figures reported by Capoor *et al.*[54] and Badiee *et al.* [55] (4.3 percent and 7 percent respectively).

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

REFERENCES

1. Kumar A, Thakur VC, Thakur S, Kumar A, Patil S. Phenotypic characterization and in vitro examination of potential virulence factors of *Candida* species isolated from a bloodstream infection. *W J Sci Techno*. 2011; 1(10):38–42.
2. Williams DW, Koriyama T, Silva S, Malic S, Lewis MAO. *Candida* biofilms and oral candidosis: treatment and prevention. *Periodontology2000*. 2011; 55:250–65.
3. Oyewole OA, Okoliegbe IN, Alkhalil S, Isah P. Prevalence of vaginal candidiasis among pregnant women attending the Federal University of Technology, Minna, Nigeria, Bosso clinic. *RJPBCS*. 2013; 4(1):113–20.
4. Deorukhkar SC, Saini S. Vulvovaginal candidiasis due to non *albicans* *Candida*: its species distribution and antifungal susceptibility profile. *Int J CurrMicrobiol App Sci*. 2013; 2(12):323–8.
5. Kumar A, Sharma PC, Kumar A, Negi V. A study on phenotypic traits of *Candida* species isolated from bloodstream infections and in vitro susceptibility to fluconazole. *Al Ameen J Med Sci*. 2014; 7(1):83–91.
6. Babic M, Hukic M. *Candida albicans* and nonalbicans species as the etiological agent of vaginitis in pregnant and non-pregnant women. *BJBMS*. 2010; 10(1):89–97.
7. Coutinho HDM. Factors influencing the virulence of *Candida* spp. *West Indian Med J*. 2009; 58(2):160.

8. Kamath P, Pais M, Nayak MG. Risk of vaginal candidiasis among pregnant women. *Int J Current Microbiol App Sci.* 2013; 2(9):141–6.
9. Esmailzadeh S, Omran S, Rahmani M. Frequency and etiology of vulvovaginal candidiasis in women referred to a gynecological Center in Babol, Iran. *Int J of Fertility and Sterility.* 2009; 3(2):74–7.
10. Hainer BL, Gibson MV. Vaginitis: diagnosis and treatment. *American Fam Physi.* 2011; 83(7):808–15.
11. Kelen FD, Datta, Alessandra R. Freitas, Marcia EL, Consolaro, Terezinha IE, Svidzinski. A Challenge for Clinical Laboratories: Detection of Antifungal Resistance in *Candida* Species Causing Vulvovaginal Candidiasis. *Journal of Labmedicine* 2011; 42: 20-30.
12. Ajitha R, Maimoona M. Phenotypic identification of *Candida* species and their susceptibility profile in patients with genitourinary candidiasis *International Journal of Advanced Research* 2014; 2: 76-84
13. Chander J. Candidiasis. In: *A textbook of Medical Mycology*, 3rd ed. Mehta Publishers, New Delhi, 2009; 266-90.
14. Kanya R, Røttingen JA, Cameron WD, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? *Sexually Transmitted Diseases.* 2001; 28(10):579- 597.
15. Bohannon NJV. Treatment of vulvovaginal candidiasis in patients with diabetes. *Diabetes Care.* 1998; 21:451-456.
16. McCormack WM, Starko KM, Zinner SH. Symptoms associated with vaginal colonization with yeast. *Am J Obstet Gynecol.* 1988; 158:31-33.
17. Reed BD. Risk factors for *Candida* vulvovaginitis. *ObstetGynecolSurv.* 1992; 47:551-560.
18. CL Roberts, JM Morris, KR Rickard et al. Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077], *BMC Pregnancy and Childbirth*, 2011; (11).
19. John EE. Mycosis. In: Mandell G L, Bennett J E, Dolin R., (editors) *Textbook of Principles and Practice of Infectious diseases.* 5th Ed. New York: Churchill Livingstone, 2000, 2291.
20. Abebe EA, Olumide M, Oke O. A manual for Health workers on Syndromic Management of STI. National AIDS and STD control program; Federal Ministry of Health Abuja, 2001, 3-7.

21. JD Sobel. Vulvovaginal candidosis, *Lancet*. 2007; 369(9577):1961-1971.
22. Kikani B, Kikani K, Pathak S. Effects of chemically synthesized azole compounds on clinical isolates of vaginal candidiasis, in comparison with commercially available drugs, *Internet J Micro- biol* 2008; 4:2.
23. Babin D, Kotigadde, Rao Sunil P and Rao TV. Clinico-mycological profile of vaginal candidiasis in a tertiary care hospital in Kerala. *International Journal of Research in Biological Sciences*, 2013; 3(1):55-59.
24. Kalia N, Singh J, Sharma S, Kamoj S, Arora H, et al. Prevalence of Vulvovaginal Infections and species specific distribution of vulvovaginal candidiasis in married women of north India. *Int. J.of Current Microbiology and Applied Sciences* 2015;4(8): 253-266.
25. Mahnaz Mahmoudi Rad, AmenehSh Zafarghandi, Maryam Amel Zabihi, Mahkam Tavallae, and YasamanMirdamadi. Identification of Candida Species Associated with Vulvovaginal Candidiasis by Multiplex PCR. *Infectious Diseases in Obstetrics and Gynecology* 2012.
26. Ibrahim Ali Altayyarl, Alliwa Shiha Alsanosil and Nazar Abdalazeem Osman: Prevalence of vaginal candidiasis among pregnant women attending different gynecological clinic at South Libya; *European Journal of Experimental Biology*, 2016, 6(3):25-29)
27. Dalia Saad ElFeky, Noha Mahmoud Gohar, Eman Ahmad El-Seidi, Mona Mahmoud Ezzat, Somaia Hassan AboElew . Species identification and antifungal susceptibility pattern of Candida isolates in cases of vulvovaginal candidiasis. *Alexandria J of Med.* (2016), 52, 269-277.
28. AyseKalkana, Ahmet Bads Ouzel, Israa Ibrahim Jabban Khalil et al. Yeast vaginitis during pregnancy:L Susceptibility testing of 13 antifungal drugs and boric acid and detection of four virulence factors: *Medical Mycology*: 2012 (50); 585-593.
29. Chander J, Singla N, Kaur S, Sidhu S. Epidemiology of Candida blood stream infections; experience of a tertiary care centre in North India: *J Inject Dev Ctries*2013; 7(9):670-675,
30. Ribeiro MA, Dietze R, Paula CR, Da Matta DA, Colombo AL. Susceptibility profile of vaginal yeast isolates from Brazil, *Mycopathologia* 2000;151:5-10.
31. Otero L, Fleites A, Mendez FJ, Palacio V, Vazquez F. Susceptibility of candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid. *European Journal of Clinical Microbiol Infect Disease* 1999; 18: 59-61.

32. Pfaller M, Diekema D, *et al.* Stability of Mueller-Hinton agar Supplemented with Glucose and Methylene Blue for Disk Diffusion Testing of Fluconazole and Voriconazole. *J. Clin. Microbiol.* 2004 ;(42)3: 128889.
33. Galan A, Veronica V, Murgui A, *et al.* Rapid PCR-based test for identifying *Candida albicans* by using primers derived from the pH-regulated KERI gene .*FEMS Yeast research* November 2006: vol(6) :Pages 1094-1100.
34. Galan A, Veronica V, Murgui A, *et al.* Rapid PCR-based test for identifying *Candida albicans* by using primers derived from the pH-regulated KERI gene .*FEMS Yeast research* November 2006: vol(6) :Pages 1094-1100.
35. Pfaller M, Diekema D, *et al.* Stability of Mueller-Hinton agar Supplemented with Glucose and Methylene Blue for Disk Diffusion Testing of Fluconazole and Voriconazole. *J. Clin. Microbiol.* March 2004;(42)3: 128889.
36. Kalpana. A study on speciation and antifungal susceptibility pattern of *Candida* isolates from HIV patients with Oropharyngeal Candidiasis and correlation with CD4 count. Madras Medical College the Tamilnadu DR.M.G.R Medical University Chennai, India march 2010.
37. Lee SC, Fung CP, Lee N, See LC, Huang JS, Tsai CJ *et al.* Fluconazole Disk Diffusion Test with Methylene Blue- and Glucose- Enriched Muller- to Fluconazole and Voriconazole by Standardized Disk Diffusion Testing. *J Clin Microbiol.* 2005; 43 (12): 5848-59
38. Kustimur S, Kalkanci A, Mansuroglu H, Senel K. evaluation of the disc diffusion method with a comparison study for fluconazole susceptibility of *Candida* strains. *Chin Med J.*2003;116 (4): 633-6.
39. Ooga VB, Gikunju JK, Bii CC. Characterization and antifungal drug susceptibility of clinical isolates of *Candida* species. *Afr J Health Sci.*2011; 19:80-7.
40. Negri M. Henriques M, Svidzinski TI, Paula CR, Oliveira R. Correlation Between Etest, Disk Diffusion, and Microdilution Methods for Antifungal Susceptibility testing of *Candida* Species from Infection and Colonization. *J. Clin Lab Anal.* 2009; 25 (5):324-30.
41. Zomorodian K, Rahimi MJ, Pakshir K, Motamedi M, Ghiasi MR, Rezashah H. determination of antifungal susceptibility patterns among the clinical isolates of *Candida* species. *J global infect Dis.* 2011; 3(4): 357-60.

42. Colombo AL, Da matta D, De Almeida LP, Rosas R. Fluconazole Susceptibility of Brazilian Candida Isolates Assessed by a Disk Diffusion
43. Kikani B, Kikani K, Pathak S. Effects of chemically synthesized azole compounds on clinical isolates of vaginal candidiasis, in comparison with commercially available drugs, Internet J Micro- biol 2008; 4:2.
44. Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselove AV et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5 year analysis of Susceptibilities of Candida and Other Yeast Species to Fluconazole and Voriconazole by Standardized Disk Diffusion testing. J Clin Microbiol. 2005; 43 (12): 5848-59.
45. Capoor MR, Nair D, Deb M, Verma PK, Srivastava L, Aggarwal P, Emergence of *non-albicans Candida* Species and Antifungal Resistance in a Tertiary Care Hospital. Jpn J Infect Dis. 2005; 58(6):344-8.
46. Doddaiah V, Dhanalakshmi T, Kulkarni S, Changing trends of vulvovaginal Candidiasis. Journal of Laboratory Physicians 2014; 6(1): 2830.
47. Whiteway M, Bachewich C. Signal transduction in the interactions of fungal pathogens and mammalian hosts. In *Molecular principles of fungal pathogenesis*. Heitman J, Filler SG, Edwards JE Jr, Mitchell AP, eds. 2006; 143-161 ASM Press, Washington DC.
48. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. J Clin Microbiol. 2007; 45 (6): 1735-45.
49. Pfaller MA, Diekema DJ, Gibbs DL, Newell V A, Ellis D, Tullio V et al. Results from the Artemis Disk Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion. J Clin Microbiol. 2010; 48 (4):1366-77.
50. Das PP, Saikia Lahari, Nath R and Phukan Sanjib Kumar. Species distribution and antifungal susceptibility pattern of oropharyngeal Candida isolates from human

- immunodeficiency virus infected individuals. Indian Journal of Medical Research 2016; 143(4):495-501.
51. Regha IR. Invitro susceptibilities of Candida isolates to Fluconazole and Voriconazole determined by disc diffusion in a tertiary care centre. South India. *Int J Res Heal Sci* 2014; 2(3):783-6.
52. Kashid RA, Belawadi S, Devi G, Indumati. Characterisation and antifungal susceptibilty testing for Candida species in a tertiary care hospital. *Journal of Health Sciences and Research*. 2011; 2(2):1-7.
53. Negri M, Henriques M, Svidzinski TI, Paula CR, Oliveira R. Correlation Between Etest, Disk Diffusion, and Microdilution Methods for Antifungal Susceptibility testing of candida Species from Infection and Colonization. *J. Clin Lab Anal*. 2009; 25 (5):324-30.
54. Capoor MR, Nair D, Deb M, Verma PK, SrivastavaL, Aggarwal P, Emergence of *non-albicans Candida* Species and Antifungal Resistance in a Tertiary Care Hospital. *Jpn J Infect Dis*.2005;58(6):344-8.
55. Badiie P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. *Iran J Microbio*1.201 I ; 3 (4): 183-